EUVIMEDOpdag EUVIMED
Crossref

Outcomes of kidney transplantation in patients with IgA nephropathy based on induction: A UNOS data analysis

Emmanuel Albert Aydin-Ghormoz iD, Jason Perlmutter, Naoru Koizumi iD, Jorge Ortiz, Geovani Faddoul iD

Clinical Transplantation · 2024

DOI: 10.1111/ctr.15225 ↗

At a glance

Journal article in Clinical Transplantation, 2024. Written by Emmanuel Albert Aydin-Ghormoz and 4 co-authors. Institution: Department of Medicine, Albany Medical Center, New York, USA. Major MEDLINE topics: Glomerulonephritis, IGA, Kidney Transplantation, Kidney Failure, Chronic. Cited 1 times so far (Crossref); 24 references. Funded by: National Science Foundation.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

IgA nephropathy (IgAN) can cause end‐stage kidney disease (ESKD). This study assesses the impact of induction and maintenance immunosuppression on IgAN recurrence, graft survival, and mortality in living and deceased donor kidney transplants (LDKT and DDKT).

Methods

Retrospective analysis of the UNOS database in adults with ESKD secondary to IgAN who received kidney transplants between January 2000 and June 30, 2022. Patients with thymoglobulin (ATG), alemtuzumab, or basiliximab/daclizumab induction with calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF) with or without prednisone maintenance were analyzed. Multivariate logistic regression was performed to identify factors correlated with IgA recurrence. Multivariable Cox regression analyses were performed for clinically suspected risk factors. Kaplan Meir Analysis was utilized for overall graft survival.

Results

Compared to ATG with steroid maintenance, alemtuzumab with steroid increased the odds of IgAN recurrence in DDKTs (OR 1.90, p < .010, 95% CI [1.169–3.101]). Alemtuzumab with and without steroid increased the odds of recurrence by 52% ( p = .036) and 56% ( p = .005), respectively, in LDKTs. ATG without steroids was associated with less risk of IgAN recurrence (HR .665, p = .044, 95% CI [.447–.989]), graft failure (HR .758, p = .002, 95% CI [.633–.907]), and death (HR .619, p < .001, 95% CI [.490–.783]) in DDKTs. Recurrence was strongly associated with risks of graft failure in DDKTs and LDKTs and death in LDKTs.

Conclusion

In patients with IgAN requiring a kidney transplant, Alemtuzumab induction correlates with increased IgAN recurrence. Relapse significantly affects graft survival and mortality. ATG without steroids is associated with the least graft loss and mortality.

Subjects

MeSH terms (MEDLINE)

Glomerulonephritis, IGAKidney TransplantationKidney Failure, ChronicAdultHumansImmunosuppressive AgentsAlemtuzumabRetrospective StudiesSteroidsGraft SurvivalGraft Rejection

Author keywords

IgAalemtuzumabbasiliximabdaclizumabkidneynephropathyoutcomethymoglobulintransplant

Substances

Immunosuppressive AgentsAlemtuzumabSteroids

Authors and institutions

  • Department of Medicine, Albany Medical Center, New York, USA.
  • Schar School of Policy & Government, George Mason University, Arlington, Virginia, USA.
  • Department of Surgery, Erie County Medical Center, Buffalo, New York, USA.

ORCID profiles: Emmanuel Albert Aydin-Ghormoz, Naoru Koizumi, Geovani Faddoul

Funding

  • National Science Foundation

Cite

APA

Aydin-Ghormoz, E. A., Perlmutter, J., Koizumi, N., Ortiz, J., & Faddoul, G. (2024). Outcomes of kidney transplantation in patients with IgA nephropathy based on induction: A UNOS data analysis. Clinical Transplantation. https://doi.org/10.1111/ctr.15225

Vancouver

Aydin-Ghormoz EA, Perlmutter J, Koizumi N, Ortiz J, Faddoul G. Outcomes of kidney transplantation in patients with IgA nephropathy based on induction: A UNOS data analysis. Clinical Transplantation. 2024. doi:10.1111/ctr.15225

BibTeX
@article{AydinGhormoz2024,
  author = {Aydin-Ghormoz, Emmanuel Albert and Perlmutter, Jason and Koizumi, Naoru and Ortiz, Jorge and Faddoul, Geovani},
  title = {Outcomes of kidney transplantation in patients with IgA nephropathy based on induction: A UNOS data analysis},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.15225}
}
Start for free →